FDA Grants Breakthrough Therapy Designation to Kowa's Pemafibrate (K-808) for Primary Biliary Cholangitis
核心洞察
Kowa Company (搜索) received FDA Breakthrough Therapy designation on June 11, 2026, for pemafibrate (K-808) as a treatment for primary biliary cholangitis (搜索) (PBC).
The designation was based on preliminary Phase II data suggesting significant improvement in alkaline phosphatase (ALP) levels over existing treatments, presented at EASL Congress in May 2026.
Pemafibrate is a selective PPARα (搜索) modulator (SPPARMα) already marketed in Japan as Parmodia for hyperlipidemia since 2018.
Kowa Company (搜索), Ltd. announced on June 30, 2026, that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to its investigational agent K-808 (pemafibrate) for the treatment of patients with primary biliary cholangitis (搜索) (PBC). The designation, officially received on June 11, 2026, marks a significant regulatory milestone for the selective PPARα (搜索) modulator (SPPARMα) in a disease with considerable unmet medical need.
The FDA's Breakthrough Therapy designation program is designed to expedite the development and review of drugs for which preliminary clinical evidence suggests a substantial improvement over existing treatments on one or more clinically important endpoints for serious diseases.
Phase II Evidence Supporting the Designation
The Breakthrough Therapy designation was granted based on preliminary data and evidence from the ongoing Phase II clinical trial (K-808-2.01). According to Kowa, results from this trial suggest a significant improvement over existing treatments as measured by a reduction in alkaline phosphatase (ALP) levels. Preliminary data were presented at the European Association for the Study of the Liver (EASL) Congress held in May 2026.
Mechanism of Action and Development Rationale
Pemafibrate is a selective PPARα (搜索) modulator developed by Kowa that comprehensively improves lipid metabolism, primarily by regulating the expression of target genes involved in lipid and glucose metabolism in the liver. In Japan, the drug has been marketed under the brand name Parmodia Tablets since June 1, 2018, for the treatment of hyperlipidemia.
For PBC, pemafibrate is expected to exert therapeutic effects through multiple mechanisms, including micellization of hydrophobic bile acids, anti-inflammatory effects resulting from activation of the nuclear receptor PPARα (搜索), and inhibition of bile acid synthesis. Kowa is developing the agent with the goal of delaying disease progression in PBC patients.
Target Indication and Global Ambitions
Kowa is advancing K-808 with the aim of obtaining global approval, including in the United States and Japan, for the treatment of PBC. The intended use is in combination with ursodeoxycholic acid (UDCA) in adult patients who have an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. Through this development program, Kowa aims to provide new treatment options to a greater number of PBC patients.
Disease Background
Primary biliary cholangitis (搜索) is a chronic, progressive cholestatic liver disease and a severe, life-threatening autoimmune liver disease. As inflammation and destruction of the intrahepatic bile ducts progress, the condition may potentially result in fibrosis, cirrhosis, and liver failure. Clinical symptoms include fatigue and pruritus, which can be extremely severe in some patients. PBC is a rare disease that primarily affects women.